Siren Biotechnology today announced the publication of its first peer-reviewed manuscript in Molecular Therapy Oncology, alongside upcoming presentations at the American Society of Gene and Cell ...
Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present k ...
Computational and preclinical data support advancement of LTS-201 and LTS-101 programs into clinic later this yearLatus ...
Dyno Therapeutics to present new capsids and AI advancements in gene delivery at the 29th American Society of Gene & Cell Therapy Annual Meeting ...
At a median 13 years after a single infusion of AAV-mediated gene therapy, factor IX expression remained stable in 10 patients with severe hemophilia B. The median annualized bleeding rate decreased ...
— Finding Hope for FRRS1L plans to initiate clinical trial using TfR1 CapX gene therapy in the second half of 2026, pending regulatory review — FORT COLLINS, Colo. and NEW YORK, Feb. 18, 2026 ...
IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology stud ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results